- $10.58bn
- $8.91bn
- $804.03m
- 68
- 13
- 59
- 43
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 229 | 485 | 667 | 804 |
Cost of Revenue | ||||
Gross Profit | 174 | 412 | 562 | 693 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Total Operating Expenses | 291 | 612 | 839 | 944 |
Operating Profit | -62.6 | -127 | -172 | -140 |
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -59.1 | -128 | -158 | -87 |
Provision for Income Taxes | ||||
Net Income After Taxes | -59.2 | -128 | -159 | -90.8 |
Net Income Before Extraordinary Items | ||||
Net Income | -59.2 | -128 | -159 | -90.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -59.2 | -128 | -159 | -90.8 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.372 | -0.808 | -1.01 | -0.571 |
Dividends per Share |